Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
CNY17.50
+1.64 (+10.34%)
CN SHH Healthcare Biotechnology
Address
No.32 Fengjin Road 231131
Hefei, CN
Hefei, CN
CEO
Henghua Guo
Website
huahengbio.com
IPO
2021-04-22
ISIN CNE1000052M6
Description
Anhui Huaheng Biotechnology Co., Ltd. specializes in the research, manufacturing, and international distribution of amino acids and various organic acids. The company's product range encompasses L-alanine, DL-alanine, beta-alanine, and D-alanine, as well as L-aspartic, DL-aspartic, D-aspartic acids, and L-aspartate salt. Additionally, it provides an array of other amino acids and arbutin products. These ingredients are widely utilized in pharmaceuticals, healthcare goods, food and food additives, daily personal care items, and other diverse industrial applications. Founded in Hefei, China, in 2005, the company operated as Anhui Huaheng Biological Engineering Co., Ltd. until its name officially changed to Anhui Huaheng Biotechnology Co., Ltd. in November 2013.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY17.50
+1.64 (+10.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.05
Float Shares
160.16M
Free Float %
64.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.92% | -7.23% | -16.18% | -34.07% | -28.84% | -27.96% | -24.41% | -70.27% | -15.21% | +39.95% | +39.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.50
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.96
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+31.4% ★ Q1'26: +12.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-35.4% Q1'26: -15.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-6.4% Q1'26: -20.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+5.9% ★ Q1'26: +7.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+3.8% ★ Q1'26: +4.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+8.9% Q1'26: -2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×5.47× Q1'26: 11.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
954.10M
est: 954.14M (0.0%)
|
1.42B
est: 1.37B (+3.5%)
|
1.94B
est: 2.10B (-7.9%)
|
2.18B
est: 2.12B (+2.9%)
|
2.86B
est: 2.88B (-0.6%)
|
3.38B
2.90B – 3.87B
+17.4% YoY
|
4.10B
3.31B – 4.89B
+21.2% YoY
|
4.59B
3.80B – 5.37B
+11.9% YoY
|
| EBITDA |
239.94M
est: 243.10M (-1.3%)
|
402.67M
est: 349.24M (+15.3%)
|
618.31M
est: 489.76M (+26.2%)
|
381.09M
est: 492.58M (-22.6%)
|
384.19M
est: 670.25M (-42.7%)
|
787.14M
674.60M – 899.67M
+17.4% YoY
|
953.99M
769.32M – 1.14B
+21.2% YoY
|
1.07B
884.75M – 1.25B
+11.9% YoY
|
| EBIT |
192.44M
est: 190.04M (+1.3%)
|
343.52M
est: 273.01M (+25.8%)
|
519.47M
est: 371.40M (+39.9%)
|
242.44M
est: 373.54M (-35.1%)
|
169.39M
est: 508.27M (-66.7%)
|
596.91M
511.57M – 682.25M
+17.4% YoY
|
723.44M
583.40M – 863.48M
+21.2% YoY
|
809.37M
670.93M – 947.81M
+11.9% YoY
|
| Net Income |
168.24M
est: 170.94M (-1.6%)
|
320.03M
est: 308.11M (+3.9%)
|
449.06M
est: 407.53M (+10.2%)
|
189.52M
est: 206.65M (-8.3%)
|
132.41M
est: 230.61M (-42.6%)
|
292.15M
283.53M – 328.84M
+26.7% YoY
|
405.48M
379.68M – 451.26M
+38.8% YoY
|
649.63M
416.98M – 655.44M
+60.2% YoY
|
| SGA |
79.93M
est: 88.21M (-9.4%)
|
142.22M
est: 126.72M (+12.2%)
|
172.08M
est: 187.70M (-8.3%)
|
221.48M
est: 188.78M (+17.3%)
|
204.44M
est: 256.87M (-20.4%)
|
301.67M
258.54M – 344.80M
+17.4% YoY
|
365.62M
294.84M – 436.39M
+21.2% YoY
|
409.04M
339.08M – 479.01M
+11.9% YoY
|
| EPS |
0.81
est: 0.74 (+9.5%)
|
1.41
est: 1.33 (+5.8%)
|
1.96
est: 1.77 (+10.6%)
|
0.82
est: 0.82 (-0.2%)
|
0.53
est: 0.92 (-42.2%)
|
1.22
1.13 – 1.31
+32.8% YoY
|
1.65
1.51 – 1.79
+35.7% YoY
|
2.13
1.66 – 2.61
+29.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
114.53M
OE per share TTM
0.49
Owner's Yield
1.95%
Maintenance CapEx ratio
171.93%
Maint CapEx / Avg PPE
115.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 14.7K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 6.5K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 725.3K | 0.06% |
| 4 | Vanguard ESG International Stock ETF VSGX | 0.00% | 9.9K | 0.10% |
| 5 | Vanguard Total International Stock ETF VXUS | 0.00% | 925.3K | 0.05% |
| 6 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.2K | 0.22% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.5K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.9K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 831.47 | 0.22% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 17.1K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
77.3K
Shares Outstanding
250.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chengxiu Han | Core technical personnel | — | male |
| Dongzhu Zhang | Deputy GM & Director | — | male |
| Henghua Guo | Chairman of the Board & GM | — | female |
| Jian Wen Mao | Deputy GM & Director | — | male |
| Liu Lei | Core technical personnel | — | male |
| Shupeng Liu | Core technical personnel | — | male |
| Siqing Tang | Core technical personnel | — | male |
| Xiu Fa Zhu | Accounting Supervisor | — | — |
| Xueli Zhang | Director & Core Technical Personnel | — | male |
| Yi Fan | CFO, Deputy GM & Director | — | male |
| Zhicheng Liu | Project Manager of MA | — | male |
| Zhong Cheng Liu | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688639.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
